Yeun Mi Yim

604 total citations
27 papers, 427 citations indexed

About

Yeun Mi Yim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Yeun Mi Yim has authored 27 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Economics and Econometrics. Recurrent topics in Yeun Mi Yim's work include Economic and Financial Impacts of Cancer (10 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). Yeun Mi Yim is often cited by papers focused on Economic and Financial Impacts of Cancer (10 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). Yeun Mi Yim collaborates with scholars based in United States and Canada. Yeun Mi Yim's co-authors include Annie Guérin, William B. Wong, Martin Cloutier, Marjolaine Gauthier‐Loiselle, Patrick Gagnon‐Sanschagrin, Carolina Reyes, Elaine Yu, Diana Chen, Stacey DaCosta Byfield and Charles S. Cleeland and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Yeun Mi Yim

24 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yeun Mi Yim United States	11	270	139	94	76	68	27	427
Lee Schwartzberg United States	8	333 1.2×	133 1.0×	104 1.1×	39 0.5×	113 1.7×	17	603
C.A. Uyl-de Groot Netherlands	12	258 1.0×	54 0.4×	115 1.2×	34 0.4×	54 0.8×	28	553
Andy Surinach United States	13	199 0.7×	81 0.6×	36 0.4×	78 1.0×	72 1.1×	74	430
Chie Akiba United States	5	223 0.8×	131 0.9×	107 1.1×	63 0.8×	60 0.9×	7	597
Anne Cowppli‐Bony France	12	159 0.6×	106 0.8×	17 0.2×	79 1.0×	27 0.4×	17	351
Danila Comandini Italy	11	269 1.0×	191 1.4×	31 0.3×	39 0.5×	29 0.4×	31	446
Toufic Eid Lebanon	11	279 1.0×	87 0.6×	38 0.4×	81 1.1×	62 0.9×	20	520
Young Jl France	5	190 0.7×	66 0.5×	26 0.3×	47 0.6×	38 0.6×	6	403
Matthew Perry United States	8	294 1.1×	136 1.0×	17 0.2×	103 1.4×	65 1.0×	13	458
N. Iscoe Canada	14	358 1.3×	170 1.2×	39 0.4×	58 0.8×	131 1.9×	26	594

Countries citing papers authored by Yeun Mi Yim

Since Specialization

Citations

This map shows the geographic impact of Yeun Mi Yim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yeun Mi Yim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yeun Mi Yim more than expected).

Fields of papers citing papers by Yeun Mi Yim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yeun Mi Yim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yeun Mi Yim. The network helps show where Yeun Mi Yim may publish in the future.

Co-authorship network of co-authors of Yeun Mi Yim

This figure shows the co-authorship network connecting the top 25 collaborators of Yeun Mi Yim. A scholar is included among the top collaborators of Yeun Mi Yim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yeun Mi Yim. Yeun Mi Yim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stevens, Vanessa, David D. Stenehjem, Olga V. Patterson, et al.. (2018). Characterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record review. Archives of Dermatological Research. 310(6). 505–513. 3 indexed citations

Borghaei, Hossein, Yeun Mi Yim, Annie Guérin, et al.. (2018). Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer. 119. 112–119. 10 indexed citations

Wong, William B., Yeun Mi Yim, Martin Cloutier, et al.. (2018). Assessment of costs associated with adverse events in patients with cancer. PLoS ONE. 13(4). e0196007–e0196007. 125 indexed citations

Fisher, Maxine D., Rajeshwari Punekar, Yeun Mi Yim, et al.. (2017). Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings. Journal of Oncology Practice. 13(1). e37–e46. 23 indexed citations

Yim, Yeun Mi, A. Guérin, Raluca Ionescu‐Ittu, et al.. (2016). Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC). Annals of Oncology. 27. vi424–vi424. 1 indexed citations

Chang, Chun‐Lan, Vernon F. Schabert, Julie Munakata, et al.. (2015). Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Research. 25(4). 312–320. 22 indexed citations

Hansson, Johan, Karen Bartley, Jean‐Jacques Grob, et al.. (2015). 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study. European Journal of Cancer. 51. S680–S681. 1 indexed citations

Gibney, Geoffrey T., Geneviève Gauthier, Eric Q. Wu, et al.. (2015). Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting. Cancer Medicine. 4(8). 1205–1213. 19 indexed citations

Cleeland, Charles S., Musa Mayer, Nancy A Dreyer, et al.. (2014). Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. The Breast. 23(6). 763–769. 53 indexed citations

10.

Mathias, Susan D., Mary‐Margaret Chren, Hilary H. Colwell, et al.. (2013). Assessing Health-Related Quality of Life for Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome. JAMA Dermatology. 150(2). 169–169. 18 indexed citations

11.

Byfield, Stacey DaCosta, Diana Chen, Yeun Mi Yim, & Carolina Reyes. (2013). Age distribution of patients with advanced non-melanoma skin cancer in the United States. Archives of Dermatological Research. 305(9). 845–850. 43 indexed citations

12.

Cartwright, Thomas H., et al.. (2012). P-0243 CLinical Outcomes of Bevacizumab used in Community Oncology Metastatic Colorectal Cancer (MCRC) Patients with Confirmed Kras-Status. Annals of Oncology. 23. iv99–iv99. 1 indexed citations

13.

Shankaran, Veena, David Mummy, Lisel Koepl, et al.. (2012). Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 12(3). 204–213.e1. 10 indexed citations

14.

Cartwright, Thomas H., et al.. (2012). Survival Outcomes of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Treated in US Community Oncology. Clinical Colorectal Cancer. 11(4). 238–246. 28 indexed citations

15.

Walker, Mark S., et al.. (2012). Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. BMC Research Notes. 5(1). 314–314. 15 indexed citations

16.

Kaufman, Peter A., Musa Mayer, Nancy A Dreyer, et al.. (2012). Patient-reported outcomes (PRO) in patients with metastatic breast cancer (MBC) from the VIRGO observational cohort study (OCS).. Journal of Clinical Oncology. 30(27_suppl). 111–111. 4 indexed citations

17.

Yu, Edward, et al.. (2011). 6150 POSTER Survival Outcomes With Use of Bevacizumab Beyond Progression (BBP) in Metastatic Colorectal Cancer (MCRC) Patients (Pts). European Journal of Cancer. 47. S437–S437.

18.

Yang, Hongbo, Andrew P. Yu, Eric Q. Wu, Yeun Mi Yim, & Elaine Yu. (2011). Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. Journal of Medical Economics. 14(5). 542–552. 8 indexed citations

19.

Walker, Mark S., et al.. (2011). Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health and Quality of Life Outcomes. 9(1). 46–46. 14 indexed citations

20.

Tierce, Jonothan C., et al.. (2009). Patient out-of-pocket payments for oral oncologic therapies: Updated results from a U.S. claims data analysis. Journal of Clinical Oncology. 27(15_suppl). 6582–6582. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact